Matthew D Coates,Shannon Dalessio,August Stuart et al.
Matthew D Coates et al.
Introduction: Hypoalgesic or silent inflammatory bowel disease (IBD) is a poorly understood condition that has been associated with poor clinical outcomes. There is evidence that lifestyle factors, including diet, exercis...
Real-World Data on Short-Term and Long-Term Treatment Results of Ustekinumab in Patients with Steroid-Resistant/Dependent Ulcerative Colitis [0.03%]
乌司奴单抗治疗糖皮质激素抵抗或依赖型溃疡性结肠炎患者的短期和长期疗效的现实世界数据
Yoriaki Komeda,George Tribonias,Masashi Kono et al.
Yoriaki Komeda et al.
Introduction: Ustekinumab is an IgG1 kappa monoclonal antibody directed against the common p40 subunit of interleukin-12 and interleukin-23, which activate Th1- and Th17-mediated immune responses, respectively. It has pro...
Milan Ultrasound Criteria Predict Relapse of Ulcerative Colitis in Remission [0.03%]
米兰超声检查标准可预测溃疡性结肠炎缓解患者的复发
Masa Maeda,Shintaro Sagami,Moyu Tashima et al.
Masa Maeda et al.
Introduction: Bowel ultrasound is a noninvasive alternative to endoscopy for assessing the disease activity of ulcerative colitis; however, it is unclear whether bowel ultrasound can predict subsequent relapse from remiss...
Spirochetosis Mimicking Acute Appendicitis: Clinical Report and Review of the Literature [0.03%]
梅毒模仿急性阑尾炎的病例报告及文献回顾
Magdalena Lüthy,Samuel A Käser,Carolin Wagener et al.
Magdalena Lüthy et al.
Introduction: Intestinal spirochetosis is sometimes found by chance in histological specimen of routine endoscopies. There are only a few cases described in the literature that spirochetosis of the appendix was mimicking ...
Detection Rates of Non-Cavitary Epithelioid Cell Granuloma by Gastrointestinal Biopsy in Patients with Treatment-Naïve Crohn's Disease [0.03%]
未经治疗的克罗恩病患者胃肠活检发现非空洞上皮样细胞肉芽肿的检出率
Katsuya Endo,Yoko Kawakami,Yuki Yoshino et al.
Katsuya Endo et al.
Introduction: Detecting non-cavitary epithelioid cell granuloma by gastrointestinal biopsy is important in the initial diagnosis of Crohn's disease (CD). In the present study, we aimed to determine the rate of granuloma d...
Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix Study [0.03%]
评估戈利木单抗治疗日本溃疡性结肠炎患者疗效及应答影响因素的现实临床研究（PHOENIX研究）
Daisuke Hirayama,Satoshi Motoya,Toshifumi Ashida et al.
Daisuke Hirayama et al.
Introduction: There have been limited reports on the clinical efficacy of golimumab (GLM) in Japanese patients with ulcerative colitis (UC) in real clinical practice. This study aimed to explore the real-life effectivenes...
Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction [0.03%]
诱导8周以上的不同剂量美沙拉嗪延续治疗对轻至中度溃疡性结肠炎临床及内镜疗效的影响评估
Geert D&#x;Haens,Ekaterina Safroneeva,Helen Thorne et al.
Geert D&#x;Haens et al.
Introduction: High-strength mesalazine formulations play an important role in providing a convenient option to increase the dose in ulcerative colitis (UC) patients and therefore avoiding the switch to another therapeutic...
Usefulness of Serum Leucine-Rich Alpha-2 Glycoprotein as a Surrogate Marker of Small Bowel Mucosal Injury in Crohn's Disease [0.03%]
血清亮氨酸富集α2糖蛋白作为克罗恩病小肠黏膜损伤替代标志物的临床价值评估
Takuto Saiki,Takehiro Torisu,Akira Harada et al.
Takuto Saiki et al.
Introduction: Although the importance of mucosal healing has been suggested in Crohn's disease, it is difficult to repeat endoscopy, especially for the entire small bowel. Recently, serum leucine-rich alpha-2 glycoprotein...
Associations between Pouchitis and Fecal Calprotectin after Restorative Proctocolectomy in Patients with Ulcerative Colitis [0.03%]
溃疡性结肠炎患者的回肠储袋肛管吻合术后 pouchitis 与粪便 calprotectin 的相关性研究
Motoi Uchino,Yuki Horio,Ryuichi Kuwahara et al.
Motoi Uchino et al.
Introduction: Recently, fecal calprotectin has been identified and used as an assessment tool for the confirmation of disease activity in ulcerative colitis. Although a meta-analysis suggested the usefulness of fecal calp...
Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis [0.03%]
乌司奴单抗治疗溃疡性结肠炎的真实世界有效性及其停药因素和风险因素分析
Genta Uchida,Masanao Nakamura,Takeshi Yamamura et al.
Genta Uchida et al.
Introduction: Ustekinumab (UST) has been approved for the treatment of moderate-to-severe ulcerative colitis (UC). Real-world data showing the effectiveness and safety of UST are necessary to confirm the results of clinic...